Agomelatine as monotherapy for major depression: an outpatient, open-label study [Corrigendum]

Pecenak J, Novotny V. Neuropsychiatric Disease and Treatment 2013;9:1595–1604.On page 1601, line 1 in the right-hand column, note that the drug "venlafaxine" is incorrect and should instead be "fluoxetine". The correct sentence is "The response rate in the current...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Pecenak J, Novotny V
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2013
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/2c174cbcfa864d1aa3e1fa12daf2caec
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:2c174cbcfa864d1aa3e1fa12daf2caec
record_format	dspace
spelling	oai:doaj.org-article:2c174cbcfa864d1aa3e1fa12daf2caec2021-12-02T00:58:10ZAgomelatine as monotherapy for major depression: an outpatient, open-label study [Corrigendum]1176-63281178-2021https://doaj.org/article/2c174cbcfa864d1aa3e1fa12daf2caec2013-11-01T00:00:00Zhttp://www.dovepress.com/corrigendum-agomelatine-as-monotherapy-for-major-depression-an-ou-a15090https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021Pecenak J, Novotny V. Neuropsychiatric Disease and Treatment 2013;9:1595–1604.On page 1601, line 1 in the right-hand column, note that the drug "venlafaxine" is incorrect and should instead be "fluoxetine". The correct sentence is "The response rate in the current study was much higher than in the 6-week and 8-week double-blind, placebo-controlled studies of agomelatine13,36 and higher than in an observational study of different antidepressants where a 38.2% early remission rate and a 20.5% early response rate were found at week 6 of treatment,41 but similar to a double-blind study comparing agomelatine with fluoxetine in patients with severe depression."42Read the original articlePecenak JNovotny VDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2013, Iss default, Pp 1827-1828 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Pecenak J Novotny V Agomelatine as monotherapy for major depression: an outpatient, open-label study [Corrigendum]
description	Pecenak J, Novotny V. Neuropsychiatric Disease and Treatment 2013;9:1595–1604.On page 1601, line 1 in the right-hand column, note that the drug "venlafaxine" is incorrect and should instead be "fluoxetine". The correct sentence is "The response rate in the current study was much higher than in the 6-week and 8-week double-blind, placebo-controlled studies of agomelatine13,36 and higher than in an observational study of different antidepressants where a 38.2% early remission rate and a 20.5% early response rate were found at week 6 of treatment,41 but similar to a double-blind study comparing agomelatine with fluoxetine in patients with severe depression."42Read the original article
format	article
author	Pecenak J Novotny V
author_facet	Pecenak J Novotny V
author_sort	Pecenak J
title	Agomelatine as monotherapy for major depression: an outpatient, open-label study [Corrigendum]
title_short	Agomelatine as monotherapy for major depression: an outpatient, open-label study [Corrigendum]
title_full	Agomelatine as monotherapy for major depression: an outpatient, open-label study [Corrigendum]
title_fullStr	Agomelatine as monotherapy for major depression: an outpatient, open-label study [Corrigendum]
title_full_unstemmed	Agomelatine as monotherapy for major depression: an outpatient, open-label study [Corrigendum]
title_sort	agomelatine as monotherapy for major depression: an outpatient, open-label study [corrigendum]
publisher	Dove Medical Press
publishDate	2013
url	https://doaj.org/article/2c174cbcfa864d1aa3e1fa12daf2caec
work_keys_str_mv	AT pecenakj agomelatineasmonotherapyformajordepressionanoutpatientopenlabelstudycorrigendum AT novotnyv agomelatineasmonotherapyformajordepressionanoutpatientopenlabelstudycorrigendum
_version_	1718403373645955072

Agomelatine as monotherapy for major depression: an outpatient, open-label study [Corrigendum]

Ejemplares similares